Sailong Pharmaceutical Group Co.,Ltd. (SHE:002898)
China · Delayed Price · Currency is CNY 8.30
0.00 (0.00%)
Apr 30, 2026, 3:04 PM CST
SHE:002898 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 616.24 | 516.83 | 261.06 | 303.51 | 261.14 | 244.05 |
Other Revenue | 1.93 | 1.93 | 2.51 | 7.12 | 3.05 | 3.03 |
| 618.17 | 518.76 | 263.57 | 310.63 | 264.19 | 247.08 | |
Revenue Growth (YoY) | 149.09% | 96.82% | -15.15% | 17.58% | 6.93% | 104.73% |
Cost of Revenue | 569.95 | 461.77 | 176.78 | 171.11 | 127.84 | 86.71 |
Gross Profit | 48.23 | 56.99 | 86.78 | 139.52 | 136.35 | 160.37 |
Selling, General & Admin | 68.02 | 72.16 | 81.29 | 106.81 | 142.59 | 157.22 |
Research & Development | 12.62 | 16.18 | 24.51 | 27.53 | 23.5 | 21.41 |
Other Operating Expenses | 9.34 | 6.58 | 3.36 | 3.2 | 4.93 | 4.76 |
Operating Expenses | 93.52 | 99.69 | 109.5 | 126.14 | 178.8 | 186.36 |
Operating Income | -45.3 | -42.7 | -22.72 | 13.38 | -42.44 | -25.99 |
Interest Expense | -6.86 | -7.2 | -6.73 | -6.91 | -8.08 | -6.6 |
Interest & Investment Income | 3.01 | 3.06 | 0.43 | 0.68 | 1.26 | 9.81 |
Other Non Operating Income (Expenses) | -2.86 | -2.68 | 0.28 | 1.05 | -0.69 | -0.65 |
EBT Excluding Unusual Items | -52.01 | -49.53 | -28.73 | 8.21 | -49.96 | -23.43 |
Gain (Loss) on Sale of Investments | -0.42 | -0.35 | - | 7.59 | 17.09 | 6.73 |
Gain (Loss) on Sale of Assets | 0.18 | -0.03 | -0.9 | 1.06 | 0.46 | -0.01 |
Asset Writedown | -65.57 | -65.44 | -6.59 | -0.01 | 0.02 | -0.13 |
Other Unusual Items | 0.11 | 0.42 | 1.3 | 5.52 | 2.71 | 3.07 |
Pretax Income | -117.71 | -114.93 | -34.92 | 22.36 | -29.67 | -13.77 |
Income Tax Expense | 9.65 | 6.93 | -1.77 | 12.82 | 7.64 | 9.57 |
Earnings From Continuing Operations | -127.36 | -121.86 | -33.15 | 9.53 | -37.31 | -23.34 |
Minority Interest in Earnings | -1.76 | 0.69 | - | - | - | - |
Net Income | -129.12 | -121.17 | -33.15 | 9.53 | -37.31 | -23.34 |
Net Income to Common | -129.12 | -121.17 | -33.15 | 9.53 | -37.31 | -23.34 |
Shares Outstanding (Basic) | 176 | 176 | 176 | 176 | 176 | 176 |
Shares Outstanding (Diluted) | 176 | 176 | 176 | 176 | 176 | 176 |
Shares Change (YoY) | 0.05% | -0.02% | 0.07% | -0.06% | -0.01% | 0.01% |
EPS (Basic) | -0.73 | -0.69 | -0.19 | 0.05 | -0.21 | -0.13 |
EPS (Diluted) | -0.73 | -0.69 | -0.19 | 0.05 | -0.21 | -0.13 |
Free Cash Flow | -5.93 | -4.29 | -73.53 | 5.13 | -9.82 | 3.99 |
Free Cash Flow Per Share | -0.03 | -0.02 | -0.42 | 0.03 | -0.06 | 0.02 |
Dividend Per Share | - | - | - | 0.020 | - | - |
Gross Margin | 7.80% | 10.99% | 32.93% | 44.91% | 51.61% | 64.91% |
Operating Margin | -7.33% | -8.23% | -8.62% | 4.31% | -16.06% | -10.52% |
Profit Margin | -20.89% | -23.36% | -12.58% | 3.07% | -14.12% | -9.45% |
Free Cash Flow Margin | -0.96% | -0.83% | -27.90% | 1.65% | -3.72% | 1.61% |
EBITDA | 8.86 | 7.06 | 9.45 | 46.28 | -9.35 | 5.59 |
EBITDA Margin | 1.43% | 1.36% | 3.59% | 14.90% | -3.54% | 2.26% |
D&A For EBITDA | 54.16 | 49.76 | 32.17 | 32.9 | 33.09 | 31.58 |
EBIT | -45.3 | -42.7 | -22.72 | 13.38 | -42.44 | -25.99 |
EBIT Margin | -7.33% | -8.23% | -8.62% | 4.31% | -16.06% | -10.52% |
Effective Tax Rate | - | - | - | 57.36% | - | - |
Revenue as Reported | 618.17 | 518.76 | 263.57 | 310.63 | 264.19 | 247.08 |
Advertising Expenses | - | 0.38 | 0.48 | 0.37 | 0.16 | 0.84 |